Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07146412 · ClinicalTrials.gov registry record · NA

Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study

A NA study of Cognitive Impairment and Mild Cognitive Impairment (MCI), sponsored by HudsonAlpha Institute for Biotechnology.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT07146412: Recruiting NA study of Cognitive Impairment and Mild Cognitive Impairment (MCI), sponsored by HudsonAlpha Institute for Biotechnology.

NCT07146412 is a NA study of Cognitive Impairment and Mild Cognitive Impairment (MCI) that is actively recruiting participants, run by HudsonAlpha Institute for Biotechnology. The registered enrollment target is 200 participants, below the 664-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07146412, a NA study of Cognitive Impairment and Mild Cognitive Impairment (MCI), is actively recruiting participants, sponsored by HudsonAlpha Institute for Biotechnology.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more effective when started early. Previous studies have shown that multimodal lifestyle interventions can significantly delay the onset of Alzheimer's dementia in individuals with high risk for Alzheimer's or with Mild Cognitive Impairment (MCI). These interventions may be less effective when initiated after dementia has already been diagnosed or is more advanced. This study has two primary goals. The first goal is to assess attitudes around dementia risk for participants throughout the study as they learn of their personalized risk and possible lifestyle factors that may modify that risk. The second goal is to serve as a logistical pilot for the implementation of data collection and processing and multimodal lifestyle intervention to reduce the risk factors of dementia in individuals without current cognitive impairment but who are at high risk of progression to dementia. Secondary goals of this study include better defining what factors contribute the most risk to dementia and identifying sub-types of dementia defined by different genetic and molecular risk factors.

Primary Outcome

All participants will be offered a survey about perception of and attitudes toward dementia risk using the scaling strategy described by Kasparian and colleagues and dementia questions from Kim and colleagues (see references).

Interventions

  • BEHAVIORAL Multimodal Lifestyle Intervention

Study Locations (1)

Alabama

  • Smith Family Clinic for Genomic Medicine - Huntsville

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-05-02
Est. Completion 2026-04-30
Phase NA

What NCT07146412 shows while recruiting

NCT07146412 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 664-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (70% lower).

The record links to 4 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which Multimodal Lifestyle Intervention is the first listed.

NCT07146412 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT07146412 about?

NCT07146412 is a clinical study titled "Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study". Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more effective when started early. Previous studies have shown that multimoda...

What is the current status of trial NCT07146412?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2025-05-02. Estimated completion is 2026-04-30.

What conditions does trial NCT07146412 study?

This clinical trial studies the following conditions: Cognitive Impairment, Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Alzheimer Blood Biomarkers.

What interventions are being tested in trial NCT07146412?

The interventions under investigation include: Multimodal Lifestyle Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT07146412?

This trial is sponsored by HudsonAlpha Institute for Biotechnology, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07146412 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07146412's enrollment target sits among peer trials

200 28th of 105 higher than 78 of 105 other Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07146412, the US trial registry maintained by the National Library of Medicine. NCT07146412 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.